




MOG-AD Breakout Session

Michael Levy, MD, PhD

Associate Professor, Harvard Medical School
Research Director, Division of Neuroimmunology,
Massachusetts General Hospital

MAT-GLB-2103835 v1.0 Approval date 09/2021

What is MOG Antibody disease?



What's in a Name?




Eugene Devic (1858-1930)




The common laboratory mouse

Two Different Antibodies



AQP4/MOG Blood Tests










MOG presentation



MOG criteria



Demographics

- Bi-modal age:
 - Children with ADEM
 - Adults with optic neuritis
- Race:
 - Predominantly Caucasian
- Sex:
 - Male = Female

Hor et al., Front Neurol. 2020; 11: 501.

Classic MOG antibody MRI




Clinical: AQP4 vs. MOG

	MOG +	AQP4 +
Age	30s	40s
Gender	F>M	F>>>M
Other autoimmune conditions	+	+++
Severity of Attacks	+++	+++
Visual outcomes	Much better	Usually poor
Brain MRI	More ADEM like	Not ADEM like

Narayan R et al. *Mult Scler Relat Disord*. 2018 Oct;25:66-72

We know the target: MOG on CNS myelin



Treatment: Acute vs. Preventive



Acute



Preventive


Acute: Standard of Care

- Methylprednisolone IV 1000 mg daily (or 30 mg/kg in children) x5 days + prolonged oral taper
- No improvement: PLEX 1-1.5 volumes x5 cycles or,
- Intravenous immunoglobulin (IVIG) at 2 g/kg (divided over 1-5 days)

Preventive Therapies: Preliminary


- 1. Steroids
- 2. IVIG/SCIG
- 3. Mycophenolate mofetil/azathioprine
- 4. Tocilizumab
- 5. New ideas

Steroids



Ramanathan S. JNNP. 2018 Feb;89(2):127.


MOG Preventive Treatment: Non-Responders



Regular IVIG (n=16) ARR During Treatment 4/12

Hacohen Y, et al. JAMA Neurol. 2018 Apr 1:75(4):478-487.

Rituximab



Whittham D. et al. *MSARD*. Vol. 44, Sep 2020.